InVitria Showcases Exbumin® and Optibumin® 25 at IPEC Excipient World: Biologics Summit: Recombinant Human Serum Albumins Already Used in On-Market Approved BiologicsJUNCTION CITY, Kan., May 01, 2026 (GLOBE NEWSWIRE) -- InVitria, a global leader in chemically defined, animal-origin-free recombinant proteins for biologics manufacturing, announced its participation in the IPEC Excipient World Biologics Summit, which will take place May 4–6, 2026, in Nashville, TN. At the event, the company will highlight its recombinant human serum albumin (rHSA) portfolio, designed to support formulation stability, consistency, and performance in injectable biologics, vaccines, and advanced therapies.
